Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.
Adriana Estrada-BernalAnh T LeAndrea E DoakVijaya G TirunagaruShevan SilvaMatthew R BullJeff B SmaillAdam V PattersonChul KimStephen V LiuRobert C DoebelePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Experimental data with tarloxotinib validate the novel mechanism of action of a hypoxia-activated prodrug in cancer models by concentrating active drug in the tumor versus normal tissue, and this activity can translate into clinical activity in patients.